(Q37954582)

25 August 2017

Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study (English)

1 reference

25 August 2017

1 reference

1 reference

5

Anais Malpica

1 reference

25 August 2017

7

Karen H Lu

1 reference

25 August 2017

16

David M Gershenson

1 reference

25 August 2017

8

Anil K Sood

1 reference

25 August 2017

Diane C Bodurka

1

1 reference

25 August 2017

Michael T Deavers

2

1 reference

25 August 2017

Chunqiao Tian

3

1 reference

25 August 2017

Charlotte C Sun

4

1 reference

25 August 2017

Robert L Coleman

6

1 reference

25 August 2017

Michael J Birrer

9

1 reference

25 August 2017

Robert Ozols

10

1 reference

25 August 2017

Rebecca Baergen

11

1 reference

25 August 2017

Robert E Emerson

12

1 reference

25 August 2017

Margaret Steinhoff

13

1 reference

25 August 2017

Behnaz Behmaram

14

1 reference

25 August 2017

Golnar Rasty

15

1 reference

25 August 2017

language of work or name

English

0 references

publication date

9 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

118

1 reference

25 August 2017

3087-3094

1 reference

25 August 2017

12

1 reference

Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer

25 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

History of the FIGO cancer staging system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Observer variation in histologic classification of malignant and borderline ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

Grading ovarian serous carcinoma using a two-tier system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

inferred from DOI database lookup

7 January 2021

based on heuristic

Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

inferred from DOI database lookup

7 January 2021

based on heuristic

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26618

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.26618

1 reference

25 August 2017

1 reference